Japan's Shionogi Sues Sawai, Claiming Patent Violation For Antibiotic
This article was originally published in PharmAsia News
Two Japanese pharmaceutical companies are headed for court over a generic version of a branded biotic drug. Shionogi has sued Sawai Pharmaceutical, saying it violated the plaintiff's patent for the crystallization technique used in making Flomox (cefcapene). Shionogi's cefcapene patent expired last October and Sawai began marketing a generic of it in May. Shionogi said its crystallization patent, however, remains effective through March 2011, and that Sawai's generic violates it. (Click here for more - a subscription may be required
You may also be interested in...
Agency officials can now discuss the ideas that have been accepted, though not in great detail.
FDA requests immediate removal of ranitidine OTC and Rx drugs after third-party testing finds contaminant NDMA increases during storage, especially at higher temperatures. CDER Director Janet Woodcock asks firms to reformulate products to be stable as the ingredient remains approved.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.